211 related articles for article (PubMed ID: 32290440)
61. Telomerase-independent paths to immortality in predictable cancer subtypes.
Durant ST
J Cancer; 2012; 3():67-82. PubMed ID: 22315652
[TBL] [Abstract][Full Text] [Related]
62. Evaluation of telomere length maintenance mechanisms in adrenocortical carcinoma.
Else T; Giordano TJ; Hammer GD
J Clin Endocrinol Metab; 2008 Apr; 93(4):1442-9. PubMed ID: 18198226
[TBL] [Abstract][Full Text] [Related]
63. Immortalized cells with no detectable telomerase activity. A review.
Reddel RR; Bryan TM; Murnane JP
Biochemistry (Mosc); 1997 Nov; 62(11):1254-62. PubMed ID: 9467849
[TBL] [Abstract][Full Text] [Related]
64. Targeting the limitless replicative potential of cancer: the telomerase/telomere pathway.
Kelland L
Clin Cancer Res; 2007 Sep; 13(17):4960-3. PubMed ID: 17785545
[TBL] [Abstract][Full Text] [Related]
65. HDAC9 regulates the alternative lengthening of telomere (ALT) pathway via the formation of ALT-associated PML bodies.
Jamiruddin MR; Kaitsuka T; Hakim F; Fujimura A; Wei FY; Saitoh H; Tomizawa K
Biochem Biophys Res Commun; 2016 Dec; 481(1-2):25-30. PubMed ID: 27833022
[TBL] [Abstract][Full Text] [Related]
66. The role of recombination in telomere length maintenance.
Royle NJ; Méndez-Bermúdez A; Gravani A; Novo C; Foxon J; Williams J; Cotton V; Hidalgo A
Biochem Soc Trans; 2009 Jun; 37(Pt 3):589-95. PubMed ID: 19442255
[TBL] [Abstract][Full Text] [Related]
67. Potential clinical treatment prospects behind the molecular mechanism of alternative lengthening of telomeres (ALT).
Sun H; Chen G; Guo B; Lv S; Yuan G
J Cancer; 2023; 14(3):417-433. PubMed ID: 36860927
[TBL] [Abstract][Full Text] [Related]
68. Disease mutant analysis identifies a new function of DAXX in telomerase regulation and telomere maintenance.
Tang M; Li Y; Zhang Y; Chen Y; Huang W; Wang D; Zaug AJ; Liu D; Zhao Y; Cech TR; Ma W; Songyang Z
J Cell Sci; 2015 Jan; 128(2):331-41. PubMed ID: 25416818
[TBL] [Abstract][Full Text] [Related]
69. Telomere-based crisis: functional differences between telomerase activation and ALT in tumor progression.
Chang S; Khoo CM; Naylor ML; Maser RS; DePinho RA
Genes Dev; 2003 Jan; 17(1):88-100. PubMed ID: 12514102
[TBL] [Abstract][Full Text] [Related]
70. Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression.
Costa A; Daidone MG; Daprai L; Villa R; Cantù S; Pilotti S; Mariani L; Gronchi A; Henson JD; Reddel RR; Zaffaroni N
Cancer Res; 2006 Sep; 66(17):8918-24. PubMed ID: 16951210
[TBL] [Abstract][Full Text] [Related]
71. Alternative Lengthening of Telomeres in Pediatric High-Grade Glioma and Therapeutic Implications.
Umaru B; Sengupta S; Senthil Kumar S; Drissi R
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370681
[TBL] [Abstract][Full Text] [Related]
72. The Molecular Mechanisms and Therapeutic Prospects of Alternative Lengthening of Telomeres (ALT).
Sohn EJ; Goralsky JA; Shay JW; Min J
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046606
[TBL] [Abstract][Full Text] [Related]
73. The Transition between Telomerase and ALT Mechanisms in Hodgkin Lymphoma and Its Predictive Value in Clinical Outcomes.
M'kacher R; Cuceu C; Al Jawhari M; Morat L; Frenzel M; Shim G; Lenain A; Hempel WM; Junker S; Girinsky T; Colicchio B; Dieterlen A; Heidingsfelder L; Borie C; Oudrhiri N; Bennaceur-Griscelli A; Moralès O; Renaud S; Van de Wyngaert Z; Jeandidier E; Delhem N; Carde P
Cancers (Basel); 2018 May; 10(6):. PubMed ID: 29848986
[No Abstract] [Full Text] [Related]
74. Combining old and new concepts in targeting telomerase for cancer therapy: transient, immediate, complete and combinatory attack (TICCA).
Ali JH; Walter M
Cancer Cell Int; 2023 Sep; 23(1):197. PubMed ID: 37679807
[TBL] [Abstract][Full Text] [Related]
75. Expanding the chemotherapeutic potential of an established nucleoside analog with selective targeting of telomerase.
Whited TL; Taylor DJ
Mol Cell Oncol; 2018; 5(6):e1536844. PubMed ID: 30525101
[TBL] [Abstract][Full Text] [Related]
76. Specific death of ALT cells through TSPYL5 depletion.
Claude E; Episkopou H; Decottignies A
Mol Cell Oncol; 2019; 6(6):e1651603. PubMed ID: 31692925
[TBL] [Abstract][Full Text] [Related]
77. Correction to: Cancer-associated SMARCAL1 loss-of-function mutations promote alternative lengthening of telomeres and tumorigenesis in telomerase-negative glioblastoma cells.
Neuro Oncol; 2023 Nov; 25(11):2105. PubMed ID: 37757453
[No Abstract] [Full Text] [Related]
78. RAD54 promotes alternative lengthening of telomeres by mediating branch migration.
Mason-Osann E; Terranova K; Lupo N; Lock YJ; Carson LM; Flynn RL
EMBO Rep; 2020 Jun; 21(6):e49495. PubMed ID: 32337843
[TBL] [Abstract][Full Text] [Related]
79. Formal reply to "Alternative lengthening of telomeres is not synonymous with mutations in ATRX/DAXX".
Feuerbach L
Nat Commun; 2021 Mar; 12(1):1551. PubMed ID: 33692348
[No Abstract] [Full Text] [Related]
80. Alternative lengthening of telomeres is not synonymous with mutations in ATRX/DAXX.
de Nonneville A; Reddel RR
Nat Commun; 2021 Mar; 12(1):1552. PubMed ID: 33692341
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
